The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports
Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.
Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent
While Sun Pharma continues to demonstrate strength in its branded and specialty businesses, concerns around US generics, R&D investments, and regulatory hurdles leave brokerages divided on its outlook
Stocks to watch on February 1, Budget 2025: Stocks from sectors such as Infrastructure & Construction, Banking & Financial Services experience volatility during the budget announcement
Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent. Both profit and revenue were in line with Bloomberg estimates
Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent
Sales in India, Sun Pharma's largest revenue-generating region, rose 14 per cent to Rs 4,300 crore, or about 31 per cent of total sales
Q3 FY25 company results, January 31: Vedanta, Nuvama, Punjab National Bank, IndusInd Bank, and Bandhan Bank will be among 135 companies to release their reports for the Oct-Dec quarter
According to brokerage estimates compiled by Business Standard, Sun Pharma may see its average revenue rise by 9.51 per cent year-on-year (Y-o-Y) to Rs 13,313 crore as against Rs 12,156 crore
The acquisition is expected to be completed before March 7, 2025, subject to approval from the Ontario Superior Court of Justice
According to a regulatory filing with BSE, the agreement was signed on December 31, 2024, with the transaction expected to be completed by January 31, 2025
According to Bloomberg, 30 of 41 analysts are bullish on Sun Pharma, while the remaining seven have a neutral rating and only 4 are bearish
Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share
This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company wins its appeal, or up to two years if it loses the case entirely
Given the investments of around $576 million and the peak revenues potential upwards of $200 million, four years down the line, ICICI Securities expects some negative impact on the company
Shares of Sun Pharmaceuticals, the biggest pharmaceutical company of India fell 1.71 per cent at Rs 1870 per share on the BSE after brokerages offered mixed reviews post Q2
The company launched 14 new products in India this quarter
Sun Pharmaceutical Industries on Monday reported a 28 per cent increase in its consolidated net profit to Rs 3,040 crore in the September quarter. The drug major had posted a net profit of Rs 2,375 crore in the July-September quarter of last fiscal. Total income rose to Rs 13,645 crore in the second quarter compared to Rs 12,486 crore in the year-ago period, the Mumbai-based drug major said in a regulatory filing. "Sun has recently strengthened its specialty pipeline through an agreement with Philogen for commercialising late stage candidate Fibromun, upon approval," Dilip Shanghvi, Chairman and Managing Director of the company, said. With Fibromun, the company's product basket for dermatologists has expanded further, he added. "We shall continue to leverage our strong cash position to strengthen our pipeline with products that are close to market," Shanghvi said. Shares of the company were trading 2.22 per cent higher at Rs 1,901.55 apiece on the BSE.
Q2FY25 company results: Indian Oil, Ambuja Cements, Aditya Birla Sun Life AMC, Sun Pharma and more will report their second-quarter earnings on October 28